Back to Stocks

ERAS

Erasca, Inc.
2 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Erasca has established a formidable position in the precision oncology landscape, underpinned by breakthrough Phase 1 data for its lead asset, ERAS-0015.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the optimistic clinical narrative, Erasca faces mounting financial and legal headwinds. The first quarter of 2026 saw a staggering net loss of $183.4 million, driven in large part by a $150 million cash payment to expand territory rights in China.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every ERAS filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The latest 10-Q filing presents a company at a critical inflection point, balancing high-alpha clinical potential against significant structural risks. The data for ERAS-0015 is undeniably strong, providing a tangible catalyst for valuation growth as the company moves toward pivotal milestones. However, the massive $150 million territory expansion payment and the sudden onset of IP litigation from Revolution Medicines create a volatile risk profile for investors. Ultimately, the investment thesis now hinges on two factors: the outcome of the IP dispute and the company's ability to maintain its funding runway without excessive dilution. While the current cash pile is substantial, the burn rate and future milestone obligations suggest that the 'fortress balance sheet' may be more temporary than it appears. Investors must weigh the potential for a best-in-class oncology blockbuster against the very real possibility of legal setbacks and continued capital erosion.

Selected Quarter

Core Takeaway

Erasca has a potential best-in-class asset and strong short-term liquidity, but new patent litigation and high cash burn create significant downside risk.

Investor Lens

The trade-off is between the high-reward potential of a pan-RAS inhibitor and the binary risk of a patent loss or funding shortfall.

Watch Next

The outcome of the Revolution Medicines IP dispute and Phase 1 data for ERAS-4001 in H2 2026.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)-0.10Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 11

Successfully raised $242.7 million in an underwritten offering in January 2026.

capital raise
90%
bearishMay 11

Received IP infringement and trade secret misappropriation allegations from Revolution Medicines.

regulatory action
70%
bearishMay 11

Net loss expanded to $183.4 million due to high IPR&D costs and operational burn.

margin compression
60%
neutralMay 11

Terminated the Novartis naporafenib program to prioritize the RAS-targeting franchise.

divestiture
40%
bullishMay 11

Successfully raised $242.7 million in an underwritten offering in January 2026.

capital raise
90%
bearishMay 11

Received IP infringement and trade secret misappropriation allegations from Revolution Medicines.

regulatory action
70%
bearishMay 11

Net loss expanded to $183.4 million due to high IPR&D costs and operational burn.

margin compression
60%
neutralMay 11

Terminated the Novartis naporafenib program to prioritize the RAS-targeting franchise.

divestiture
40%

Filing History

10-QMay 11, 2026
Expand Sequence

The latest 10-Q filing presents a company at a critical inflection point, balancing high-alpha clinical potential against significant structural risks. The data for ERAS-0015 is undeniably strong, providing a tangible catalyst for valuation growth as the company moves toward pivotal milestones. However, the massive $150 million territory expansion payment and the sudden onset of IP litigation from Revolution Medicines create a volatile risk profile for investors. Ultimately, the investment thesis now hinges on two factors: the outcome of the IP dispute and the company's ability to maintain its funding runway without excessive dilution. While the current cash pile is substantial, the burn rate and future milestone obligations suggest that the 'fortress balance sheet' may be more temporary than it appears. Investors must weigh the potential for a best-in-class oncology blockbuster against the very real possibility of legal setbacks and continued capital erosion.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.